Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD
Completed · Phase 4
Conditions studied: Attention-Deficit/Hyperactivity Disorder, Comorbid Dyslexia
In brief
The purpose of this study is to assess the efficacy and safety of atomoxetine administered once daily in the treatment of children and adolescents with ADHD and comorbid dyslexia.
Key facts
- Study ID
- NCT00191048
- Run by
- Eli Lilly and Company
- People needed
- 105
- Starts
- 2003-10-01
- Expected to finish
- 2006-03-01
- Last updated by the study team
- 2007-01-26
Who can join
Age: 10 and older, up to 16. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with ADHD only or ADHD and Dyslexia
- At least 10 years old and no more than 16 years old
- IQ score of 80 or more
- Must be able to swallow capsules
You may not qualify if…
- Have received treatment within last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry
- Weigh less than 25 kg or greater than 70 kg
- Pregnant or breast feeding
- Documented history of bipolar I or II disorder, or psychosis
- Documented history of autism, Asperger's syndrome or pervasive developmental disorder
Where it is running
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician — Rolling Hills Estate, California, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician — Maitland, Florida, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician — Miami, Florida, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician — Libertyville, Illinois, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician — Las Vegas, Nevada, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician — Oklahoma City, Oklahoma, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician — Nashville, Tennessee, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician — Burlington, Vermont, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.